New insights into the pathophysiology of multiple myeloma

Lancet Oncology

Volumn 4, Issue 9, 2003, Pages 557-564

  Seidl, Sonja ^a   Kaufmann, Hannes ^a   Drach, Johannes ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN D3; CYTOKINE; FIBROBLAST GROWTH FACTOR RECEPTOR 3; IMMUNOGLOBULIN HEAVY CHAIN; K RAS PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MYC PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TRANSCRIPTION FACTOR; IMMUNOGLOBULIN;

B LYMPHOCYTE; BONE MARROW; CANCER CLASSIFICATION; CANCER GROWTH; CELL GROWTH; CELL SURVIVAL; CHROMOSOME 11Q; CHROMOSOME 13Q; CHROMOSOME 16Q; CHROMOSOME 4P; CHROMOSOME 6P; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHROMOSOME STRUCTURE; CLINICAL FEATURE; EPIGENETICS; GENE ACTIVATION; GENE CONTROL; GENE EXPRESSION PROFILING; GENE LOCUS; GENE MUTATION; GENE TRANSLOCATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MICROENVIRONMENT; MOLECULAR CLONING; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; ONCOGENE; ONCOGENE C MYC; ONCOGENE K RAS; ONCOGENE N RAS; OSTEOCLAST; PATHOPHYSIOLOGY; PLASMA CELL; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STROMA CELL; TREATMENT PLANNING; TUMOR SUPPRESSOR GENE; GENETICS;

CHROMOSOME ABERRATIONS; HUMANS; IMMUNOGLOBULINS; MULTIPLE MYELOMA; TRANSLOCATION, GENETIC;

EID: 0141765902     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(03)01195-1     Document Type: Review

References (74)

1. Calame K.L. Plasma cells: finding new light at the end of B cell development Nat Immunol 2 2001 1103-1108
2. Bakkus M.H. Heirman C. Van Riet I. et al. Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation Blood 80 1992 2326-2335
3. Sahota S.S. Garand R. Mahroof R. et al. V(H) gene analysis of IgM-secreting myeloma indicates an origin from a memory cell undergoing isotype switch events Blood 94 1999 1070-1076
4. Sahota S.S. Leo R. Hamblin T.J. Stevenson F.K. Ig VH gene mutational patterns indicate different tumor cell status in human myeloma and monoclonal gammopathy of undetermined significance Blood 87 1996 746-755
5. Vescio R.A. Cao J. Hong C.H. et al. Myeloma Ig heavy chain V region sequences reveal prior antigenic selection and marked somatic mutation but no intraclonal diversity J Immunol 155 1995 2487-2497
6. Zandecki M. Lai J.L. Facon T. Multiple myeloma: almost all patients are cytogenetically abnormal Br J Haematol 94 1996 217-227
7. Debes-Marun C.S. Dewald G.W. Bryant S. et al. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma Leukemia 17 2003 427-436
8. Smadja N.V. Bastard C. Brigaudeau C. et al. Hypodiploidy is a major prognostic factor in multiple myeloma Blood 98 2001 2229-2238
9. Fonseca RBE, Paz NG, Picken EB, et al. Two major cytogenetic subtypes of multiple myeloma (MM) can be discerned, hyperdiploid-MM and non-hyperdiploid-MM, the latter with a strong association with IgH translocations (IgH-TRX). Proceedings of the American Society of Hematology, Philadelphia, USA, 2002: 100a (370).
10. Willis T.G. Dyer M.J. The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies Blood 96 2000 808-822
11. Bergsagel P.L. Chesi M. Nardini E. et al. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma Proc Natl Acad Sci USA 93 1996 13931-13936
12. Avet-Loiseau H. Daviet A. Brigaudeau C. et al. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Groupe Francais de Cytogenetique Hematologique Blood 97 2001 822-825
13. Avet-Loiseau H. Facon T. Daviet A. et al. 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma Cancer Res 59 1999 4546-4550
14. Fonseca R. Bailey R.J. Ahmann G.J. et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance Blood 100 2002 1417-1424
15. Moreau P. Facon T. Leleu X. et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy Blood 100 2002 1579-1583
16. Ronchetti D. Finelli P. Richelda R. et al. Molecular analysis of 11q13 breakpoints in multiple myeloma Blood 93 1999 1330-1337
17. Janssen J.W. Vaandrager J.W. Heuser T. et al. Concurrent activation of a novel putative transforming gene, myeov, and cyclin D1 in a subset of multiple myeloma cell lines with t(11;14)(q13;q32) Blood 95 2000 2691-2698
18. Avet-Loiseau H. Garand R. Lode L. et al. Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants Blood 101 2003 1570-1571
19. Chesi M. Nardini E. Brents L.A. et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3 Nat Genet 16 1997 260-264
20. Plowright E.E. Li Z. Bergsagel P.L. et al. Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis Blood 95 2000 992-998
21. Chesi M. Brents L.A. Ely S.A. et al. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma Blood 97 2001 729-736
22. Pollett J.B. Trudel S. Stern D. et al. Overexpression of the myeloma-associated oncogene fibroblast growth factor receptor 3 confers dexamethasone resistance Blood 100 2002 3819-3821
23. Santra M. Zhan F. Tian E. et al. A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lack FGFR3 expression but maintain an IGH/MMSET fusion transcript Blood 14 2002 14
24. Keats J.J. Reiman T. Maxwell C.A. et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression Blood 101 2003 1520-1529
25. Chesi M. Bergsagel P.L. Shonukan O.O. et al. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma Blood 91 1998 4457-4463
26. Shaughnessy J. Jr Gabrea A. Qi Y. et al. Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma Blood 98 2001 217-223
27. Fonseca R. Blood E. Rue M. et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma Blood 6 2003 6
28. Janz S. Potter M. Rabkin C.S. Lymphoma and leukemia-associated chromosomal translocations in healthy individuals Genes Chromosomes Cancer 36 2003 211-223
29. Tricot G. Barlogie B. Jagannath S. et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities Blood 86 1995 4250-4256
30. Perez-Simon J.A. Garcia-Sanz R. Tabernero M.D. et al. Prognostic value of numerical chromosome aberrations in multiple myeloma: a FISH analysis of 15 different chromosomes Blood 91 1998 3366-3371
31. Zojer N. Konigsberg R. Ackermann J. et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization Blood 95 2000 1925-1930
32. Fonseca R. Oken M.M. Harrington D. et al. Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy Leukemia 15 2001 981-986
33. Desikan R. Barlogie B. Sawyer J. et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities Blood 95 2000 4008-4010
34. Fonseca R. Harrington D. Oken M.M. et al. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study Cancer Res 62 2002 715-720
35. Facon T. Avet-Loiseau H. Guillerm G. et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy Blood 97 2001 1566-1571
36. Fassas A.B. Spencer T. Sawyer J. et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma Br J Haematol 118 2002 1041-1047
37. Elnenaei M.O. Hamoudi R.A. Swansbury J. et al. Delineation of the minimal region of loss at 13q14 in multiple myeloma Genes Chromosomes Cancer 36 2003 99-106
38. Drach J. Angerler J. Schuster J. et al. Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance Blood 86 1995 3915-3921
39. Konigsberg R. Ackermann J. Kaufmann H. et al. Deletions of chromosome 13q in monoclonal gammopathy of undetermined significance Leukemia 14 2000 1975-1979
40. Sibley K. Fenton J.A. Dring A.M. et al. A molecular study of the t(4;14) in multiple myeloma Br J Haematol 118 2002 514-520
41. Avet-Loiseau H. Li J.Y. Morineau N. et al. Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma Blood 94 1999 2583-2589
42. Shou Y. Martelli M.L. Gabrea A. et al. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma Proc Natl Acad Sci USA 97 2000 228-233
43. Liu P. Leong T. Quam L. et al. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial Blood 88 1996 2699-2706
44. Kalakonda N. Rothwell D.G. Scarffe J.H. Norton J.D. Detection of N-Ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma at presentation Blood 98 2001 1555-1560
45. Bezieau S. Devilder M.C. Avet-Loiseau H. et al. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis Hum Mutat 18 2001 212-224
46. Neri A. Baldini L. Trecca D. et al. p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy Blood 81 1993 128-135
47. Drach J. Ackermann J. Fritz E. et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy Blood 92 1998 802-809
48. Ng M.H. Chung Y.F. Lo K.W. et al. Frequent hypermethylation of p16 and p15 genes in multiple myeloma Blood 89 1997 2500-2506
49. Mateos M.V. Garcia-Sanz R. Lopez-Perez R. et al. Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival Br J Haematol 118 2002 1034-1040
50. Guillerm G. Gyan E. Wolowiec D. et al. p16(INK4a) and p15(INK4b) gene methylations in plasma cells from monoclonal gammopathy of undetermined significance Blood 98 2001 244-246
51. Ng M.H. To K.W. Lo K.W. et al. Frequent death-associated protein kinase promoter hypermethylation in multiple myeloma Clin Cancer Res 7 2001 1724-1729
52. Galm O. Yoshikawa H. Esteller M. et al. SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma Blood 27 2002 27
53. Wijermans P. Lubbert M. Verhoef G. et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients J Clin Oncol 18 2000 956-962
54. Zhan F. Hardin J. Kordsmeier B. et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells Blood 99 2002 1745-1757
55. De Vos J. Couderc G. Tarte K. et al. Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays Blood 98 2001 771-780
56. Hallek M. Bergsagel P.L. Anderson K.C. Multiple myeloma: increasing evidence for a multistep transformation process Blood 91 1998 3-21
57. Klein B. Cytokine, cytokine receptors, transduction signals, and oncogenes in human multiple myeloma Semin Hematol 32 1995 4-19
58. Urashima M. Ogata A. Chauhan D. et al. Transforming growth factor-beta 1: differential effects on multiple myeloma versus normal B cells Blood 87 1996 1928-1938
59. Zhang B. Gojo I. Fenton R.G. Myeloid cell factor-1 is a critical survival factor for multiple myeloma Blood 99 2002 1885-1893
60. Derenne S. Monia B. Dean N.M. et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells Blood 100 2002 194-199
61. Hideshima T. Chauhan D. Schlossman R. et al. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications Oncogene 20 2001 4519-4527
62. Podar K. Tai Y.T. Davies F.E. et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration Blood 98 2001 428-435
63. Georgii-Hemming P. Wiklund H.J. Ljunggren O. Nilsson K. Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines Blood 88 1996 2250-2258
64. Qiang Y.W. Kopantzev E. Rudikoff S. Insulin like growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk Blood 99 2002 4138-4146
65. Standal T. Borset M. Lenhoff S. et al. Serum insulin like growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor Blood 100 2002 3925-3929
66. Magrangeas F. Nasser V. Avet-Loiseau H. et al. Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease Blood 6 2003 6
67. Anderson K.C. Moving disease biology from the lab to the clinic Cancer 97 2003 796-801
68. Giuliani N. Bataille R. Mancini C. et al. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment Blood 98 2001 3527-3533
69. Sezer O. Heider U. Zavrski I. et al. RANK ligand and osteoprotegerin in myeloma bone disease Blood 101 2003 2094-2098
70. Giuliani N. Colla S. Sala R. et al. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease Blood 100 2002 4615-4621
71. Choi S.J. Cruz J.C. Craig F. et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma Blood 96 2000 671-675
72. Choi S.J. Oba Y. Gazitt Y. et al. Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease J Clin Invest 108 2001 1833-1841
73. Croucher P.I. Shipman C.M. Van Camp B. Vanderkerken K. Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease Cancer 97 2003 818-824
74. Claudio J.O. Masih-Khan E. Tang H. et al. A molecular compendium of genes expressed in multiple myeloma Blood 100 2002 2175-2186